Galderma Group AG/ADR
GALDYNext catalyst
Nemolizumab
Prurigo Nodularis
Get an email about GALDY's next catalysts
Track Galderma Group AG/ADR (GALDY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
2 upcoming, 1 past
nemolizumab Phase 2 Est. Readout (CPUO)
Estimated primary completion for nemolizumab trial (NCT07074977) in Chronic Pruritus of Unknown Origin. Topline data typically follows completion by weeks to months.
Phase II data show long-term symptom relief in children aged 2 to 11 years with moderate-to-severe atopic dermatitis
SourceNemolizumab Phase 3 Est. Readout
Estimated primary completion for Nemolizumab trial (NCT07762833) in Atopic Dermatitis. Topline data typically follows completion by weeks to months.
SourceHow GALDY's past catalysts played out
Market Overview
Stock performance and key metrics
Corticosteroid 3 - C. propionate
Scalp Psoriasis
Metvix and natural daylight PDT
Actinic Keratoses
Adapalene BPO Gel standard daily overnight application
Acne
botulinum toxin neuromodulator
Glabellar Lines
Metvix® cream
Superficial Basal Cell Carcinoma
clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)
Scalp Seborrheic Dermatitis
Benzoyl Peroxide
Acne Vulgaris
GK567
Malodorous Infected Cutaneous Ulcer
Adapalene/BPO gel with Lymecycline capsules
Acne Vulgaris
NDL-PDT
Actinic Keratoses
PDT with Metvix
Basal Cell Carcinoma
CD0271/CD1579
Acne Vulgaris
Ivermectin
Papulopustular Rosacea
Brimonidine tartrate was applied cutaneously once daily
Rosacea
tretinoin emollient
Photoaging
clobetasol propionate shampoo (2/week)
Scalp Seborrheic Dermatitis
calcitriol ointment
Psoriasis
Tretinoin
Lentigo
C. propionate -Corticosteroid 3
Scalp Psoriasis
clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)
Scalp Seborrheic Dermatitis
Adapalene-BPO Gel every other day application
Acne
Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion
Acne
Adapalene-BPO 3-hour daily application before bedtime
Acne
C. propionate- Corticosteroid 2
Scalp Psoriasis
Corticosteroid 1- C. propionate
Scalp Psoriasis
Corticosteroid 2 - C. propionate
Scalp Psoriasis
MAL
Actinic Keratoses
OnabotulinumtoxinA
Moderate to Severe Glabellar Lines
Azelaic acid
Papulopustular Rosacea (PPR)
CD5789 (trifarotene)
Acne Vulgaris
AbobotulinumtoxinA
Glabellar Frown Lines
CD0271
Acne Vulgaris
Metvix cream
Basal Cell Carcinoma
C. propionate - Corticosteroid 1
Scalp Psoriasis
Adapalene/BPO
Acne Vulgaris
Adapalene BPO
Acne Vulgaris
Clobex® Shampoo
Scalp Psoriasis
Botulinum Toxin Type A (Azzalure)
Aging
clobetasol propionate
Psoriasis
Trifarotene
Acne Vulgaris
CD07805/47 Gel
Rosacea
botulinum toxin
Glabellar Frown Lines
Adapalene
Photoaging
GK530G
Acne Vulgaris
CD5024
Papulopustular Rosacea
Epiduo/Tactuo
Acne
QM1114-DP
Glabellar Frown Lines
Adapalene/Benzoyl Peroxide
Acne Vulgaris
Botulinum Toxin Type A
Canthal Lines
Nemolizumab
Prurigo Nodularis
Adapalene BPO Gel associated with Doxycyline Hyclate
Severe Acne Vulgaris
Adapalene lotion
Acne Vulgaris
Metvix
Photoaged Skin
CD1579
Acne Vulgaris
CYP 450 Substrates
Atopic Dermatitis
CD5789
Acne Vulgaris
CD14152 Dose A
Prurigo Nodularis
AbobotulinumtoxinA dose 3
Platysmal Bands
CD 2027
Psoriasis
CD11301
Cutaneous T Cell Lymphoma
COL-118 facial gel (brimonidine)
Erythematous Rosacea
Calcitriol
Chronic Plaque Psoriasis
Botulinum Toxin Type A - Azzalure
Wrinkles
CD2475/101
Acne Vulgaris
AbobotulinumtoxinA dose level 1 or 2
Glabellar Frown Lines
AbobotulinumtoxinA dose 2
Platysmal Bands
AbobotulinumtoxinA dose 1
Platysmal Bands
CD07223
Acne
CD2027
Atopic Dermatitis
NP000888
Psoriasis
AbobotulinumtoxinA dose 4
Glabellar Frown Lines
CD10367 Solution - Non-desquamated zone
Psoriasis Vulgaris
CD0271/CD1579 gel
Acne
CD07805/47
Erythematotelangiectatic Rosacea
CD10367 Solution - Desquamated zone
Psoriasis Vulgaris
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Corticosteroid 3 - C. propionate | Phase 3 | Scalp Psoriasis | - | - |
Metvix and natural daylight PDT | Phase 3 | Actinic Keratoses | - | - |
Adapalene BPO Gel standard daily overnight application | Phase 3 | Acne | - | - |
botulinum toxin neuromodulator | Phase 3 | Glabellar Lines | - | - |
Metvix® cream | Phase 3 | Superficial Basal Cell Carcinoma | - | - |
clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week) | Phase 3 | Scalp Seborrheic Dermatitis | - | - |
Benzoyl Peroxide | Phase 3 | Acne Vulgaris | - | - |
GK567 | Phase 3 | Malodorous Infected Cutaneous Ulcer | - | - |
Adapalene/BPO gel with Lymecycline capsules | Phase 3 | Acne Vulgaris | - | - |
NDL-PDT | Phase 3 | Actinic Keratoses | - | - |
PDT with Metvix | Phase 3 | Basal Cell Carcinoma | - | - |
CD0271/CD1579 | Phase 3 | Acne Vulgaris | - | - |
Ivermectin | Phase 3 | Papulopustular Rosacea | - | - |
Brimonidine tartrate was applied cutaneously once daily | Phase 3 | Rosacea | - | - |
tretinoin emollient | Phase 3 | Photoaging | - | - |
clobetasol propionate shampoo (2/week) | Phase 3 | Scalp Seborrheic Dermatitis | - | - |
calcitriol ointment | Phase 3 | Psoriasis | - | - |
Tretinoin | Phase 3 | Lentigo | - | - |
C. propionate -Corticosteroid 3 | Phase 3 | Scalp Psoriasis | - | - |
clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week) | Phase 3 | Scalp Seborrheic Dermatitis | - | - |
Adapalene-BPO Gel every other day application | Phase 3 | Acne | - | - |
Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion | Phase 3 | Acne | - | - |
Adapalene-BPO 3-hour daily application before bedtime | Phase 3 | Acne | - | - |
C. propionate- Corticosteroid 2 | Phase 3 | Scalp Psoriasis | - | - |
Corticosteroid 1- C. propionate | Phase 3 | Scalp Psoriasis | - | - |
Corticosteroid 2 - C. propionate | Phase 3 | Scalp Psoriasis | - | - |
MAL | Phase 3 | Actinic Keratoses | - | - |
OnabotulinumtoxinA | Phase 3 | Moderate to Severe Glabellar Lines | - | - |
Azelaic acid | Phase 3 | Papulopustular Rosacea (PPR) | - | Patent 2029 |
CD5789 (trifarotene) | Phase 3 | Acne Vulgaris | - | - |
AbobotulinumtoxinA | Phase 3 | Glabellar Frown Lines | - | - |
CD0271 | Phase 3 | Acne Vulgaris | - | - |
Metvix cream | Phase 3 | Basal Cell Carcinoma | - | - |
C. propionate - Corticosteroid 1 | Phase 3 | Scalp Psoriasis | - | - |
Adapalene/BPO | Phase 3 | Acne Vulgaris | - | - |
Adapalene BPO | Phase 3 | Acne Vulgaris | - | - |
Clobex® Shampoo | Phase 3 | Scalp Psoriasis | - | - |
Botulinum Toxin Type A (Azzalure) | Phase 3 | Aging | - | - |
clobetasol propionate | Phase 3 | Psoriasis | - | - |
Trifarotene | Phase 3 | Acne Vulgaris | - | - |
CD07805/47 Gel | Phase 3 | Rosacea | - | - |
botulinum toxin | Phase 3 | Glabellar Frown Lines | - | - |
Adapalene | Phase 3 | Photoaging | - | - |
GK530G | Phase 3 | Acne Vulgaris | - | - |
CD5024 | Phase 3 | Papulopustular Rosacea | - | - |
Epiduo/Tactuo | Phase 3 | Acne | - | - |
QM1114-DP | Phase 3 | Glabellar Frown Lines | - | - |
Adapalene/Benzoyl Peroxide | Phase 3 | Acne Vulgaris | - | - |
Botulinum Toxin Type A | Phase 3 | Canthal Lines | - | - |
Nemolizumab | Phase 3 | Prurigo Nodularis | - | - |
Adapalene BPO Gel associated with Doxycyline Hyclate | Phase 3 | Severe Acne Vulgaris | - | - |
Adapalene lotion | Phase 3 | Acne Vulgaris | - | - |
Metvix | Phase 2 | Photoaged Skin | - | - |
CD1579 | Phase 2 | Acne Vulgaris | - | - |
CYP 450 Substrates | Phase 2 | Atopic Dermatitis | - | - |
CD5789 | Phase 2 | Acne Vulgaris | - | - |
CD14152 Dose A | Phase 2 | Prurigo Nodularis | - | - |
AbobotulinumtoxinA dose 3 | Phase 2 | Platysmal Bands | - | - |
CD 2027 | Phase 2 | Psoriasis | - | - |
CD11301 | Phase 2 | Cutaneous T Cell Lymphoma | - | - |
COL-118 facial gel (brimonidine) | Phase 2 | Erythematous Rosacea | - | - |
Calcitriol | Phase 2 | Chronic Plaque Psoriasis | - | - |
Botulinum Toxin Type A - Azzalure | Phase 2 | Wrinkles | - | - |
CD2475/101 | Phase 2 | Acne Vulgaris | - | - |
AbobotulinumtoxinA dose level 1 or 2 | Phase 2 | Glabellar Frown Lines | - | - |
AbobotulinumtoxinA dose 2 | Phase 2 | Platysmal Bands | - | - |
AbobotulinumtoxinA dose 1 | Phase 2 | Platysmal Bands | - | - |
CD07223 | Phase 2 | Acne | - | - |
CD2027 | Phase 2 | Atopic Dermatitis | - | - |
NP000888 | Phase 2 | Psoriasis | - | - |
AbobotulinumtoxinA dose 4 | Phase 2 | Glabellar Frown Lines | - | - |
CD10367 Solution - Non-desquamated zone | Phase 2 | Psoriasis Vulgaris | - | - |
CD0271/CD1579 gel | Phase 2 | Acne | - | - |
CD07805/47 | Phase 2 | Erythematotelangiectatic Rosacea | - | - |
CD10367 Solution - Desquamated zone | Phase 2 | Psoriasis Vulgaris | - | - |
Actinic Keratoses
3 drugs in this indication
Acne Vulgaris
3 drugs in this indication
Acne
2 drugs in this indication
Cutaneous T Cell Lymphoma
2 drugs in this indication
Erythematous Rosacea
2 drugs in this indication
Papulopustular Rosacea (PPR)
2 drugs in this indication
Photoaged Skin
2 drugs in this indication
Moderate to Severe Glabellar Lines
1 drug in this indication
Glabellar Frown Lines
1 drug in this indication
Glabellar Lines
1 drug in this indication
Prurigo Nodularis
1 drug in this indication
Chronic Plaque Psoriasis
1 drug in this indication
Rosacea
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
moderate-to-severe atopic dermatitis in children aged 2 to 11 years
1 drug in this indication
Frown lines
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Galderma Group AG/ADR's drug pipeline?→
CatalystAlert tracks 75 drug candidates in Galderma Group AG/ADR's (GALDY) pipeline across Phase 3, Phase 2. Its lead program is Nemolizumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Galderma Group AG/ADR's next FDA catalyst?→
Galderma Group AG/ADR's (GALDY) next tracked catalyst is a Phase 3 readout expected Q4 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GALDY biotech catalysts?→
Add GALDY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Galderma Group AG/ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.